Company Overview
iRhythm Holdings, Inc. functions as a digital healthcare entity dedicated to the design, development, and commercialization of device-based technology designed to provide ambulatory cardiac monitoring services for the diagnosis of arrhythmias within the United States. The company operates within the Healthcare sector, specifically the Medical Devices industry, positioning itself at the intersection of advanced technology and critical patient diagnostics. The organization employs approximately 2,400 individuals and holds a market capitalization of $3.81 billion while generating annual revenue of $747.14 million. These financial figures indicate a substantial market presence, reflecting the company's significant operational scale and its established role as a major player in the specialized cardiac monitoring landscape.
Financial Health
iRhythm Holdings reported revenue of $747.14 million for the trailing twelve months, yet this revenue generated a net income of -$44,551,000 and an EBITDA of -$30,568,000. The substantial gap between the positive revenue figure and the negative net income reveals a cost structure where operating expenses, likely driven by research and development or sales initiatives, significantly outpace gross profit generation in the current period. Despite the negative earnings, the company maintains a positive free cash flow of $71.67 million, which provides a critical layer of financial flexibility allowing the firm to fund operations or strategic initiatives without relying solely on external capital markets. The company's profitability is reflected in margins that show a gross margin of 70.6%, an operating margin of 4.2%, and a profit margin of -6.0%. The high gross margin indicates efficient production or sales of the monitoring devices, whereas the low positive operating margin and negative profit margin suggest that overhead costs and other expenses are consuming a significant portion of revenue. On the balance sheet, the company holds $583.76 million in cash against $731.18 million in debt, resulting in a debt-to-equity ratio of 478.69. This specific ratio indicates a highly leveraged balance sheet where debt obligations substantially exceed equity capitalization. However, the current ratio stands at 4.63, which indicates robust short-term liquidity suggesting the company possesses ample current assets to cover its current liabilities. Return on Equity is recorded at -36.6% and Return on Assets at -2.4%, metrics that reveal that management is currently generating negative returns on the capital invested by shareholders and the asset base.
Valuation Assessment
Valuation metrics for iRhythm Holdings include a P/E Ratio (TTM) that is N/A due to negative earnings, contrasted with a forward P/E of 140.83. The significant disparity between a non-existent trailing P/E and a high forward P/E implies that the market is pricing in a substantial expected turnaround in earnings trajectory over the coming periods. The stock trades at a price-to-book ratio of 24.91, which indicates a high market premium over the company's net asset value, suggesting investors are willing to pay significantly more than the book value for future growth potential. Alternative valuation measures show a price-to-sales ratio of 5.09 and an EV/EBITDA of -129.34, suggesting that traditional earnings-based valuation models are not applicable and that the market is relying on sales multiples or cash flow metrics given the negative earnings environment. The stock's recent trading range is defined by a 52-week high of $212.00 and a 52-week low of $92.52. To calculate the current position relative to this range, one must note that the forward P/E of 140.83 and price-to-sales of 5.09 generally correlate with a trading price near the upper end of the recent volatility spectrum, though the specific current share price is not listed in the provided facts to calculate the exact percentage distance from the high or low. The stock exhibits a beta of 1.15, which means the price volatility is 15% higher than the broader market, indicating that the stock will likely amplify market movements during periods of rising or falling equity markets.
Growth & Income
The company demonstrates a revenue growth rate of 27.1% year-over-year, while the earnings growth rate is N/A due to the reported net losses. Since earnings are not growing in a positive sense, the expansion in revenue does not yet translate into proportional earnings growth, implying that the company is still in a phase of heavy reinvestment or cost normalization where top-line expansion precedes bottom-line profitability. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, which explains that the firm retains all earnings to reinvest into growth initiatives rather than distributing income to shareholders. The overall growth and income profile is characterized by aggressive revenue expansion coupled with negative earnings and a lack of dividend distribution, reflecting a strategic focus on market capture and product development rather than immediate income generation for investors.